Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 49.8% in September

by · The Cerbat Gem

Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Free Report) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 141,700 shares, an increase of 49.8% from the September 15th total of 94,600 shares. Approximately 15.1% of the shares of the stock are short sold. Based on an average daily volume of 445,100 shares, the days-to-cover ratio is presently 0.3 days.

Allarity Therapeutics Stock Down 5.4 %

ALLR stock opened at $1.39 on Monday. The business has a 50-day simple moving average of $1.11 and a 200 day simple moving average of $1.10. Allarity Therapeutics has a 52 week low of $1.37 and a 52 week high of $666.00.

Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) last released its earnings results on Monday, August 5th. The company reported ($0.11) earnings per share (EPS) for the quarter. As a group, research analysts forecast that Allarity Therapeutics will post -78.08 EPS for the current fiscal year.

About Allarity Therapeutics

(Get Free Report)

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.

See Also